Patents by Inventor Chung-Ming Sun
Chung-Ming Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220306605Abstract: The present invention provides novel substituted benzimidazole derivatives used as DAAO inhibitors and for treatment and/or prevention of neurological disorders.Type: ApplicationFiled: March 30, 2022Publication date: September 29, 2022Inventors: Yufeng Jane TSENG, Yu-Li LIU, Chung-Ming SUN, Wen-Sung LAI, Chih-Min LIU, Hai-Gwo HWU
-
Publication number: 20220267301Abstract: The present invention provides novel substituted benzimidazole derivatives used as DAAO inhibitors and for treatment and/or prevention of neurological disorders.Type: ApplicationFiled: May 4, 2022Publication date: August 25, 2022Inventors: Yufeng Jane TSENG, Yu-Li LIU, Chung-Ming SUN, Wen-Sung LAI, Chih-Min LIU, Hai-Gwo HWU
-
Patent number: 11370775Abstract: The present invention provides novel substituted benzimidazole derivatives of formula (I) used as DAAO inhibitors and for treatment and/or prevention of neurological disorders.Type: GrantFiled: September 14, 2017Date of Patent: June 28, 2022Assignees: NATIONAL TAIWAN UNIVERSITY, NATIONAL YANG MING CHIAO TUNG UNIVERSITY, NATIONAL HEALTH RESEARCH INSTITUTESInventors: Yufeng Jane Tseng, Yu-Li Liu, Chung-Ming Sun, Wen-Sung Lai, Chih-Min Liu, Hai-Gwo Hwu
-
Publication number: 20200361894Abstract: The present invention provides novel substituted benzimidazole derivatives used as DAAO inhibitors and for treatment and/or prevention of neurological disorders.Type: ApplicationFiled: September 14, 2017Publication date: November 19, 2020Inventors: Yufeng Jane TSENG, Yu-Li LIU, Chung-Ming SUN, Wen-Sung LAI, Chih-Min LIU, Hai-Gwo HWU
-
Patent number: 10360710Abstract: A method of establishing virtual makeup data, an electronic device and a non-transitory computer readable storage medium are provided. The method includes: adjusting a scope of the makeup face in the first image to match a predetermined face scope in a predetermined image; defining a plurality of areas on the adjusted makeup face, and each of the areas corresponds to a makeup category; capturing a plurality of first makeup features of at least one of the target makeup category in the makeup category; comparing the first makeup features with a plurality of second makeup features in the database whose target makeup category are same; adding a first makeup pattern including the first makeup features to the target makeup category of the database when the first makeup feature is different from the second makeup feature.Type: GrantFiled: June 13, 2017Date of Patent: July 23, 2019Assignee: ASUSTeK COMPUTER INC.Inventors: Yi-Chi Cheng, Chung-Ming Sun
-
Patent number: 9868975Abstract: The invention utilizes virtual screening strategy to seek for current market drugs as anti-schizophrenia therapy drug repurposing. Drug repurposing strategy finds new uses other than the original medical indications of existing drugs. Finding new indications for such drugs will benefit patients who are in needs for a potential new therapy sooner since known drugs are usually with acceptable safety and pharmacokinetic profiles. In this study, repurposing marketed drugs for DAAO inhibitor as new schizophrenia therapy was performed with virtual screening on marketed drugs and its metabolites. The identified and available drugs and compounds were further confirmed with in vitro DAAO enzymatic inhibitory assay.Type: GrantFiled: April 30, 2015Date of Patent: January 16, 2018Assignees: National Taiwan University, National Chiao Tung University, National Health Research InstitutesInventors: Yufeng Jane Tseng, Yu-Li Liu, Chung-Ming Sun, Hai-Gwo Hwu, Chih-Min Liu, Wen-Sung Lai
-
Publication number: 20170358116Abstract: A method of establishing virtual makeup data, an electronic device and a non-transitory computer readable storage medium are provided. The method includes: adjusting a scope of the makeup face in the first image to match a predetermined face scope in a predetermined image; defining a plurality of areas on the adjusted makeup face, and each of the areas corresponds to a makeup category; capturing a plurality of first makeup features of at least one of the target makeup category in the makeup category; comparing the first makeup features with a plurality of second makeup features in the database whose target makeup category are same; adding a first makeup pattern including the first makeup features to the target makeup category of the database when the first makeup feature is different from the second makeup feature.Type: ApplicationFiled: June 13, 2017Publication date: December 14, 2017Applicant: ASUSTeK COMPUTER INC.Inventors: Yi-Chi Cheng, Chung-Ming Sun
-
Publication number: 20170037448Abstract: The invention utilizes virtual screening strategy to seek for current market drugs as anti-schizophrenia therapy drug repurposing. Drug repurposing strategy finds new uses other than the original medical indications of existing drugs. Finding new indications for such drugs will benefit patients who are in needs for a potential new therapy sooner since known drugs are usually with acceptable safety and pharmacokinetic profiles. In this study, repurposing marketed drugs for DAAO inhibitor as new schizophrenia therapy was performed with virtual screening on marketed drugs and its metabolites. The identified and available drugs and compounds were further confirmed with in vitro DAAO enzymatic inhibitory assay.Type: ApplicationFiled: April 30, 2015Publication date: February 9, 2017Inventors: Yufeng Jane TSENG, Yu-Li LIU, Chung-Ming SUN, Hai-Gwo HWU, Chih-Min LIU, Wen-Sung LAI
-
Publication number: 20160366687Abstract: A method and apparatus for delivery of control signaling in a wireless communication system are disclosed. In one embodiment, the method includes communicating with a UE (User Equipment) in the cell via downlink and uplink transmissions, wherein the downlink and uplink transmissions are organized into radio frames and each radio frame contains multiple subframes and each subframe contains multiple symbols. The method also includes transmitting, in the cell, a UE specific signal in a first symbol of a downlink control region of a subframe of the multiple subframes, wherein the network node is not allowed to transmit a common signal in the first symbol.Type: ApplicationFiled: June 7, 2016Publication date: December 15, 2016Inventors: Yu-Hsuan Guo, Ko-Chiang Lin, Richard Lee-Chee Kuo, Chung-Ming Sun
-
Patent number: 9126968Abstract: The present invention relates to a quinic acid derivative, preparation process of the same and pharmaceutical uses thereof. The quinic acid derivative has a quinic acid-like structure which binds to CD28, blocks T-cell signal 2 pathway via CD28, and suppresses T-cell activation. The C-1 carboxyl group, the C-3 hydroxyl group and the C-4 hydroxyl group of quinic acid are modified to attenuate the cytotoxicity of the quinic acid derivative. The preparation process of the quinic acid derivative comprises 2 steps of: treating quinic acid with the first reagent in the presence of the acid catalyst to form an immediate; and treating the immediate with the second reagent to from the quinic acid derivative. With the ability to suppress T-cell activation, the quinic acid derivative is used to treats an autoimmune disease, an allergy, transplant rejection or other related immune disorder.Type: GrantFiled: June 13, 2013Date of Patent: September 8, 2015Assignee: National Applied Research LaboratoriesInventors: Hueih-Min Chen, Chung-Ming Sun, Chih-Yu Huang
-
Patent number: 9029394Abstract: 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120(Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.Type: GrantFiled: May 13, 2013Date of Patent: May 12, 2015Assignee: China Medical UniversityInventors: Sheng-Chu Kuo, Che-Ming Teng, Kuo-Hsiung Lee, Li-Jiau Huang, Li-Chen Chou, Chih-Shiang Chang, Chung-Ming Sun, Tian-Shung Wu, Shiow-Lin Pan, Tzong-Der Way, Jang-Chang Lee, Jing-Gung Chung, Jai-Sing Yang, Chien-Ting Chen, Ching-Che Huang, Shih-Ming Huang
-
Patent number: 9023866Abstract: 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120(Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.Type: GrantFiled: May 13, 2013Date of Patent: May 5, 2015Assignee: China Medical UniversityInventors: Sheng-Chu Kuo, Che-Ming Teng, Kuo-Hsiung Lee, Li-Jiau Huang, Li-Chen Chou, Chih-Shiang Chang, Chung-Ming Sun, Tian-Shung Wu, Shiow-Lin Pan, Tzong-Der Way, Jang-Chang Lee, Jing-Gung Chung, Jai-Sing Yang, Chien-Ting Chen, Ching-Che Huang, Shih-Ming Huang
-
Patent number: 9023867Abstract: 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120 (Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.Type: GrantFiled: May 13, 2013Date of Patent: May 5, 2015Assignee: China Medical UniversityInventors: Sheng-Chu Kuo, Che-Ming Teng, Kuo-Hsiung Lee, Li-Jiau Huang, Li-Chen Chou, Chih-Shiang Chang, Chung-Ming Sun, Tian-Shung Wu, Shiow-Lin Pan, Tzong-Der Way, Jang-Chang Lee, Jing-Gung Chung, Jai-Sing Yang, Chien-Ting Chen, Ching-Che Huang, Shih-Ming Huang
-
Publication number: 20140371445Abstract: The present invention relates to a quinic acid derivative, preparation process of the same and pharmaceutical uses thereof. The quinic acid derivative has a quinic acid-like structure which binds to CD28, blocks T-cell signal 2 pathway via CD28, and suppresses T-cell activation. The C-1 carboxyl group, the C-3 hydroxyl group and the C-4 hydroxyl group of quinic acid are modified to attenuate the cytotoxicity of the quinic acid derivative. The preparation process of the quinic acid derivative comprises 2 steps of: treating quinic acid with the first reagent in the presence of the acid catalyst to form an immediate; and treating the immediate with the second reagent to from the quinic acid derivative. With the ability to suppress T-cell activation, the quinic acid derivative is used to treats an autoimmune disease, an allergy, transplant rejection or other related immune disorder.Type: ApplicationFiled: June 13, 2013Publication date: December 18, 2014Inventors: HUEIH-MIN CHEN, CHUNG-MING SUN, CHIH-YU HUANG
-
Publication number: 20130252999Abstract: 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120(Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.Type: ApplicationFiled: May 13, 2013Publication date: September 26, 2013Applicant: China Medical UniversityInventors: Sheng-Chu KUO, Che-Ming Teng, Kuo-Hsiung Lee, Li-Jiau Huang, Li-Chen Chou, Chih-Shiang Chang, Chung-Ming Sun, Tian-Shung Wu, Shiow-Lin Pan, Tzong-Der Way, Jang-Chang Lee, Jing-Gung Chung, Jai-Sing Yang, Chien-Ting Chen, Ching-Che Huang, Shih-Ming Huang
-
Publication number: 20130253006Abstract: 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120(Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.Type: ApplicationFiled: May 13, 2013Publication date: September 26, 2013Applicant: China Medical UniversityInventors: Sheng-Chu KUO, Che-Ming Teng, Kuo-Hsiung Lee, Li-Jiau Huang, Li-Chen Chou, Chih-Shiang Chang, Chung-Ming Sun, Tian-Shung Wu, Shiow-Lin Pan, Tzong-Der Way, Jang-Chang Lee, Jing-Gung Chung, Jai-Sing Yang, Chien-Ting Chen, Ching-Che Huang, Shih-Ming Huang
-
Publication number: 20130244983Abstract: 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120 (Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.Type: ApplicationFiled: May 13, 2013Publication date: September 19, 2013Applicant: China Medical UniversityInventors: Sheng-Chu KUO, Che-Ming TENG, Kuo-Hsiung LEE, Li-Jiau HUANG, Li-Chen CHOU, Chih-Shiang CHANG, Chung-Ming SUN, Tian-Shung WU, Shiow-Lin PAN, Tzong-Der WAY, Jang-Chang LEE, Jing-Gung CHUNG, Jai-Sing YANG, Chien-Ting CHEN, Ching-Che HUANG, Shih-Ming HUANG
-
Patent number: 8440692Abstract: 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120 (Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and ?/, ?/-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.Type: GrantFiled: December 7, 2007Date of Patent: May 14, 2013Assignee: China Medical UniversityInventors: Sheng-Chu Kuo, Che-Ming Teng, Kuo-Hsiung Lee, Li-Jiau Huang, Li-Chen Chou, Chih-Shiang Chang, Chung-Ming Sun, Tian-Shung Wu, Shiow-Lin Pan, Tzong-Der Way, Jang-Chang Lee, Jing-Gung Chung, Jai-Sing Yang, Chien-Ting Chen, Ching-Che Huang, Shih-Ming Huang
-
Patent number: 8383662Abstract: Bicyclic heteroaryl compounds of formula (I) shown below are disclosed. Each variable in formula (I) is defined in the specification. Also disclosed is treatment of cancer with these compounds.Type: GrantFiled: October 1, 2010Date of Patent: February 26, 2013Assignees: National Chiao Tung University, National Taiwan UniversityInventors: Chung-Ming Sun, Min-Liang Kuo, Yufeng Jane Tseng
-
Patent number: RE49340Abstract: The invention utilizes virtual screening strategy to seek for current market drugs as anti-schizophrenia therapy drug repurposing. Drug repurposing strategy finds new uses other than the original medical indications of existing drugs. Finding new indications for such drugs will benefit patients who are in needs for a potential new therapy sooner since known drugs are usually with acceptable safety and pharmacokinetic profiles. In this study, repurposing marketed drugs for DAAO inhibitor as new schizophrenia therapy was performed with virtual screening on marketed drugs and its metabolites. The identified and available drugs and compounds were further confirmed with in vitro DAAO enzymatic inhibitory assay.Type: GrantFiled: May 2, 2019Date of Patent: December 20, 2022Assignees: National Taiwan University, National Yang Ming Chiao Tung University, National Health Research InstitutesInventors: Yufeng Jane Tseng, Yu-Li Liu, Chung-Ming Sun, Hai-Gwo Hwu, Chih-Min Liu, Wen-Sung Lai